Publications by authors named "W C Duivenvoorden"
Article Synopsis
- Prostate cancer (PC) patients often face high rates of cardiovascular disease (CVD), which significantly impacts their survival, and recent studies are examining the relationship between these two conditions throughout treatment.
- A comprehensive review of literature from 2000 to 2024 highlights the role of CVD in PC-related mortality, risk factors, and how different treatments affect cardiovascular health, including hormonal therapies and chemotherapy.
- The conclusion emphasizes the urgent need to address CVD as a major cause of death in PC patients by understanding its complex interactions with cancer treatments and prioritizing prevention strategies and multidisciplinary care.
Cardiovascular risk in ADT recipients: does the type of ADT matter?
Prostate Cancer Prostatic Dis
September 2024
Low testosterone (T), common in aging men, associates with cardiovascular disease. We investigated whether follicle-stimulating hormone (FSH), which is affected by T, modulates the cardiovascular effects associated with low T or castration. FSHβ:low-density lipoprotein receptor (LDLR) mice, untreated or castrated (orchiectomy, gonadotropin-releasing hormone agonist or antagonist), demonstrated significantly less atherogenesis compared with similarly treated LDLR mice, but not following FSH delivery.
View Article and Find Full Text PDFArticle Synopsis
- Cardiovascular disease is a major issue for men with prostate cancer, and low testosterone levels can increase their risk of heart problems.
- A study looked at 1,326 men with prostate cancer who hadn’t started hormone therapy and found that 42% of them had low testosterone.
- Men with low testosterone were more likely to have other health issues like heart disease, diabetes, and obesity, making them at greater risk for future cardiovascular events.
Background: The presence of glycosylated isoforms of prostate-specific antigen (PSA) in prostate cancer (PC) cells is a potential marker of their aggressiveness. We characterized the origin of α2,3-sialylated prostate-specific antigen (S23PSA) by tissue-based sialylation-related gene expression and studied the performance of S23PSA density (S23PSAD) alone and in combination with multiparametric magnetic resonance imaging (MRI) for the detection of clinically significant prostate cancer in men with elevated PSA.
Methods: Tissue-based quantification of S23PSA and sialyltransferase and sialidase gene expression was evaluated in 71 radical prostatectomy specimens.